Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-01-13 Sale |
2025-01-15 5:00 pm |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
43,635 | $1.2632 | $55,120 | 49,546 (Direct) |
View |
| 2024-01-18 Sale |
2024-01-18 8:23 pm |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
5,468 | $1.1906 | $6,510 | 10,056 (Direct) |
View |
| 2021-05-17 Sale |
2021-05-17 7:12 pm |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
860 | $0.89 | $765 | 41,754 (Direct) |
View |
| 2021-02-16 Sale |
2021-02-17 5:23 pm |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
828 | $1.72 | $1,424 | 42,614 (Direct) |
View |
| 2020-11-16 Sale |
2020-11-18 4:10 pm |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
876 | $0.5211 | $456 | 25,762 (Direct) |
View |
| 2020-08-14 Sale |
2020-08-17 8:21 pm |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
872 | $0.605 | $528 | 26,638 (Direct) |
View |
| 2020-05-15 Sale |
2020-05-18 4:27 pm |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
909 | $0.6268 | $570 | 27,510 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-01-30 Option Award |
2025-01-31 5:00 pm |
N/A 2035-01-29 |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
487,500 | $0 | 487,500 (Direct) |
View |
| 2025-01-09 Option Award |
2025-01-10 5:00 pm |
N/A N/A |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
17,500 | $1.3 | 93,181 (Direct) |
View |
| 2025-01-09 Option Award |
2025-01-10 5:00 pm |
N/A N/A |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
66,625 | $1.36 | 93,181 (Direct) |
View |
| 2024-05-20 Option Award |
2024-05-21 4:20 pm |
N/A 2034-05-19 |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
363,000 | $0 | 363,000 (Direct) |
View |
| 2024-01-12 Option Award |
2024-01-17 5:04 pm |
N/A 2034-01-11 |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
81,250 | $0 | 85,524 (Direct) |
View |
| 2023-08-10 Option Award |
2023-08-14 4:12 pm |
N/A 2033-08-09 |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
393,750 | $0 | 393,750 (Direct) |
View |
| 2023-01-11 Option Award(A) |
2023-01-17 4:13 pm |
N/A 2033-01-10 |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
45,000 | $0 | 45,000 (Direct) |
View |
| 2023-01-11 Option Award |
2023-01-17 4:07 pm |
N/A 2033-01-10 |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
30,000 | $0 | 30,000 (Direct) |
View |
| 2022-05-09 Option Award |
2022-05-11 4:31 pm |
N/A 2030-01-20 |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
70,000 | $0 | 70,000 (Direct) |
View |
| 2022-01-12 Option Award |
2022-01-26 4:11 pm |
N/A 2032-01-11 |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
480,000 | $0 | 480,000 (Direct) |
View |
| 2021-02-04 Option Award |
2021-02-05 4:57 pm |
N/A 2031-02-04 |
Regulus Therapeutics Inc. | RGLS | Aker Christopher Ray Sr. VP & General Counsel |
180,000 | $0 | 180,000 (Direct) |
View |